

Impaired M₃ Muscarinic Acetylcholine Receptor Signal Transduction Through Blockade of Binding of Multiple Proteins to its Third Intracellular Loop

Dasiel O. Borroto-Escuela^{a,c}, Patricia A. Correia^b, Mileidys Perez Alea^c, Manuel Narvaez^d, Pere Garriga^c, Kjell Fuxe^a and Francisco Ciruela^e

^aNeuroscience Department, Karolinska Institutet, Stockholm, ^bW.M. Keck Centre for Integrative Neuroscience and Department of Physiology, University of California, San Francisco, ^cCentre for Molecular Biotechnology, Department of Chemical Engineering, Technical University of Catalonia, Barcelona, ^dDepartment of Physiology, School of Medicine, University of Málaga, ^eDepartment of Pathology and Experimental Therapeutic, School of Medicine, Campus Bellvitge, IDIBELL-University of Barcelona, Barcelona

Key Words

Third intracellular loop • Muscarinic receptor • Interacting proteins • G-protein coupled receptors • Protein complexes

Abstract

Several motifs found in the third intracellular loop of the M₃ muscarinic receptor are critical for G protein activation and scaffold protein interaction. However, how multiprotein complexes form is not fully understood. A minigene encoding the third intracellular loop of the M₃ muscarinic receptor was constructed to explore whether peptides from this intracellular region could act as inhibitors of the muscarinic multiprotein complex formation and signaling. We found that this construct, when co-expressed with the M₃ receptor, has the ability to act as a competitive antagonist of G protein receptors and receptor-scaffold/accessory proteins. Transient transfection of human embryonic kidney-293 cells with DNA encoding the human M₃ and M₅ receptor subtypes results in a carbachol-dependent increase of inositol phosphate. Co-expression of the M₃ third cytoplasmic loop minigene dramatically reduces both carbachol-mediated G protein activation and inositol phosphate accumulation. Minigene expression also

abrogates activation of M₃ and M₅ receptor mitogen-activated protein kinases pathway. Furthermore, minigene expression led to reduced AKT activation. These data, together with results of co-immunoprecipitation of different scaffold and kinase proteins, provide experimental evidence for the role for the third cytoplasmic loop of the human M₃ muscarinic receptor in G-protein activation and multiprotein complex formation.

Copyright © 2010 S. Karger AG, Basel

Introduction

Muscarinic acetylcholine receptors (mAChRs) belong to a class I subfamily of heptahelical, transmembrane G-protein coupled receptors (GPCRs) and are represented by five distinct subtypes, denoted as M₁, M₂, M₃, M₄ and M₅ [1, 2]. mAChRs signal through heterotrimeric guanine nucleotide-binding proteins (G-proteins), involving mainly the third intracellular loop (3ILoop). Muscarinic M₁, M₃ and M₅ receptors couple preferentially to the G_{q/11} subunit type of G-proteins, activating

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

© 2010 S. Karger AG, Basel
1015-8987/10/0255-0397\$26.00/0

Accessible online at:
www.karger.com/cpb

Dasiel O. Borroto-Escuela, PhD
Neuroscience Department, Karolinska Institutet
Retzius väg 8, Stockholm (Sweden)
Tel. +46 8 52487077, Fax +46 8 315721
E-Mail Dasiel.Borroto-Escuela@ki.se

phospholipase C- β , and inducing a subsequent increase in intracellular calcium concentration [3]. In contrast, M_2 and M_4 couple mainly to G-proteins of the $G_{i/o}$ classes, typically leading to adenylate cyclase inhibition and activation of inward-rectifier potassium conductance [4, 5]. Among other possible responses, in a suitable cellular context, all mAChR subtypes can regulate a wide network of signaling intermediates, including small GTPase Rho, phospholipase D, phosphoinositide-3 kinase, nonreceptor kinases and mitogen-activated protein kinases [6-9].

Increasing evidence indicates that signaling efficiency/specificity for mAChRs is determined in part by accessory proteins that physically interact or are found in the microenvironment of the receptor [10]. Several proteins have been shown to interact with mAChRs, including other GPCRs, kinases, and scaffold proteins such as β -arrestin [11, 12]. These proteins, along with classical core signaling entities (receptor, G protein and effectors), contribute to form a signalsome complex at the cytoplasmic face of the receptor [13]. Understanding the nature and features of such a complex may be a key step in designing novel strategies to develop next generation drugs. Sequence similarities of different receptor subtypes at the ligand binding sites is the main hurdle for designing and identifying proper subtype-selective ligands [14, 15]. However, important differences in size and sequence homology of the intracellular loops across different muscarinic receptors can be used to specifically identify each subtype. Previous studies using receptor-derived peptides from specific regions of the M_1 and M_2 receptors have shown the C-terminal tail of the 3ILoop is critical for receptor-G-protein interaction [16] and the resulting signal transduction mediated by G proteins [17]. More recently, specific motifs in the 3ILoop of M_1 and M_3 receptors have been shown to bind some accessory proteins with high affinity (calmodulin, oncogenic SET protein, and small GTPase Rho) [12, 13, 18]. This experimental evidence points to a specific role of 3ILoop in receptor-G protein coupling, signal transduction and multiprotein complex formation. Thus, we hypothesized that the soluble expressed 3ILoop could act as a 3ILoop receptor analogue, competing with the receptor for its interacting proteins, and affecting the specific G-protein-mediated downstream effects.

To verify this hypothesis, we developed a minigene construct expressing the human M_3 muscarinic acetylcholine receptor 3ILoop (M_3 R-3ILoop minigene), and evaluated its ability to affect downstream mAChRs signaling to $G_{q/11}$ proteins.

Materials and Methods

Materials

Dulbecco's modified Eagle's medium, penicillin/streptomycin and fetal bovine serum were purchased from Invitrogen (Carlsbad, CA, USA). [35 S]-GTP γ S (1,202 Ci/mmol), [3 H]-myo-inositol (3.0 Ci/ml) and N-[3 H]-methylscopolamine ([3 H]-NMS, 81 Ci/mmol), were from Amersham Biosciences (Piscataway, NJ, USA). Restriction enzymes were from New England Biolabs (Beverly, MA, USA). The rabbit anti-hemagglutinin (HA) polyclonal antibody (clone HA.11) was purchased from Covance (Berkeley, CA, USA). Carbamylcholine chloride (carbachol), atropine sulfate and all other reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA). The pcDNA3-Flag-GRK2 encoding the bovine G receptor kinase-2 was kindly provided by Y. Chen (FUMC, Shanghai, China) and the pcDNA3-Flag-CK1- α encoding the human casein kinase 1- α was kindly provided by M. Bini (Palermo University, Italy).

Plasmid constructs

The constructs presented here were made using standard techniques employing PCR and fragment replacement strategies. The cDNAs for the human M_3 and M_5 mAChRs (kindly provided by T. Bonner, NIH, USA and D. Bello, ETH, Switzerland, respectively) were subcloned into the mammalian expression vector pcDNA-3.1 (Invitrogen) containing three HA epitopes (gift from P. Calvo, SFU, CA, USA), thus resulting in the 3xHA- M_3 R-pcDNA3.1 and 3xHA- M_5 R-pcDNA3.1 vectors. Briefly, a 1.9 and 1.7 kb fragments encoding the human M_3 R and M_5 R were respectively amplified using sense and antisense primers harboring unique EcoRV and XbaI sites and then subcloned into EcoRV/XbaI sites of the mammalian pcDNA3.1-3xHA vector.

The cDNAs fragment encoding the entire third intracellular loop (3ILoop) of M_3 muscarinic acetylcholine receptor (Thr249-Ser495) was subcloned into the InterPlay $^{\circledR}$ mammalian TAP system, pNTAP-B vector (Stratagene, La Jolla, CA, USA) resulting in the pTAP- M_3 R-3ILoop vectors (M_3 R-3ILoop minigene). The 3ILoop of M_3 R was amplified from the 3xHA- M_3 R-pcDNA vectors using the Expand High Fidelity PCR System (Roche, Basel, Switzerland) and subcloned into BamHI/EcoRI sites of the pNTAP-B vector.

Cell culture and transfection

HEK293T cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (FCS), 100 U/ml streptomycin, 100 μ g/ml penicillin, 2 mM L-glutamine (all from Invitrogen) at 37°C in a humidified 5% CO $_2$ incubator. For transfections, 2×10^6 cells were seeded into 100-mm dishes. About 24 h later, cells were co-transfected with pTAP- M_3 R-3ILoop vector and the corresponding human muscarinic plasmid, by using the Lipofectamine $^{\text{TM}}$ Plus reagent (Invitrogen). Cells were harvested 48 h after transfection and centrifuged at 30000xg for 30 min. Membrane fractions were frozen as aliquots in 5 mM phosphate buffer saline (PBS), pH 7.4, and stored at -80°C until required.

M₃R-3ILoop minigene transcript analysis. HEK293T cells were washed with PBS 48h post-transfection, and total RNA was purified using Quick Prep™ total RNA extraction kit (Amersham Biosciences) and subject to RT-PCR (Access RT-PCR system; Promega, USA). Primers were selected according to Gene Bank database (forward: 5'- GCG GAT CCA CTG GAG GAT CTA TAA GG-3'; reverse: 5'- GCG AAT TCG ACC AGG GAC ATC C-3) to amplify a segment of 541 bp. A RT-PCR negative control was performed loading DEPC water instead of cDNAs and a positive control was performed using G3DPH primers.

Membrane preparation and radioligand binding assay

About 48 h after transfection, HEK293T cells were washed twice with cold PBS, harvested and homogenized in binding buffer (25 mM HEPES, pH 7.4, 5 mM MgCl₂, 1 mM EDTA), using a Polytron tissue homogeniser. Cell membranes were collected by centrifugation at 20000xg for 15 min and homogenized as above. After centrifugation at 40000xg for 20 min at 4°C, the final pellet was resuspended in binding buffer, and membranes were either used immediately or frozen in liquid nitrogen and stored at -80°C until needed. Protein concentration was determined by using the Bradford protein assay kit (Bio-Rad, Hercules, CA, USA). To determine the affinity of NMS for each sample, membranes were incubated with different concentrations of [³H]-NMS (ranging from 12.5 pM to 1.5 nM) in 5 mM sodium phosphate (pH 7.4) containing 5 mM MgCl₂ at 25°C for 60 min. The incubations were stopped by filtration through Whatman (Maidstone, Kent, UK) GF/B filters and washed extensively with ice-cold PBS before scintillation counting. Nonspecific binding was determined in the presence of 10µM atropine.

Inositol phosphate determination

Transfected HEK293T cells were labeled for 18-24 h with [³H]-myo-inositol (Amersham Biosciences) in DMEM (with glucose, w/o inositol (Invitrogen). After labeling, cells were washed and preincubated for 5 min in PBS at 37 °C, and subsequently incubated in FCS free medium with different concentrations of carbachol -or without carbachol- in the presence of 10 mM LiCl for 5 min. Reactions were stopped by perchloric acid addition. Inositol phosphates (IPs) were extracted and separated on Dowex AG1-X8 columns (Bio-Rad, Hercules, CA, USA). Total labelled IPs were then counted by liquid scintillation.

[³⁵S]-GTPγS binding assay

HEK293T cell membranes were diluted in an ice-cold buffer containing 10 mM HEPES and 0.1 mM EDTA, 5Mm deoxycholate (pH 7.4). Then pelleted and resuspended in a binding buffer consisting of 10 mM HEPES, 10 mM MgCl₂, and 100 mM NaCl (pH 7.4) at a final protein concentration of 125 µg/ml. Incubations were conducted in a final assay volume of 1 ml (125µg total protein) for 1 h at 30°C in the presence of 1 µM GDP and 0.3 nM [³⁵S]-GTPγS (Amersham Biosciences) and the suitable ligand concentration (carbachol from 1 nM to 1 mM).


The reaction was stopped by addition of 5 ml of ice-cold buffer containing HEPES/NaOH (10 mM) (pH 7.4) and MgCl₂ (1 mM), immediately followed by rapid filtration through glass fibre filters GF/C filters (Whatman) presoaked in the same buffer. The filters were washed twice with 5 ml of buffer and the radioactivity was measured by scintillation counting. Nonspecific binding was determined in the presence of 10 µM GTPγS. Assays were performed in triplicate.

Co-immunoprecipitation and western blot

To immunoprecipitate the M₃ mAChR with its associated proteins, plasmids encoding the HA-M₃R receptor as well as the β-arrestin-GFP, Flag-GRK-2 or Flag-CK1-α expressing vectors were transiently co-transfected into HEK293T cells. 48 h later, cells were serum-deprived for 4 h., then incubated with vehicle or carbachol (20 µM) for 10 min and washed once with PBS before being solubilized for immunoprecipitation. Protein immunodetection on membranes was assessed using goat anti-M₃R antibody (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-HA polyclonal antibody (1:2000; Covance), mouse anti-flag M2 monoclonal antibody (1:5000; Sigma-Aldrich) and mouse anti-GFP monoclonal antibody (1:10000; Novus Biological, Spain) as primary antibodies; and then horseradish-peroxidase (HRP) -conjugated goat anti-rabbit IgG (1:60000; Pierce, Rockford, IL, USA) or goat anti-mouse IgG (1:2000; Pierce, Rockford, IL, USA) as secondary antibody and developed using SuperSignal West Pico Chemiluminescent Substrate (Pierce).

MAPK and AKT assay. Co-transfected HEK293T cells expressing M₃ or M₅ receptor subtypes with or without the M₃R-3ILoop minigene were grown to 80% confluence and rendered quiescent by serum starvation overnight before MAPK or AKT phosphorylation assay. Subsequently, additional 2h incubation in fresh serum-free medium was performed to minimize basal activity. Then, cells were stimulated by adding medium containing the muscarinic agonist carbachol. Rapid rinsing, with ice-cold PBS finished stimulation, and then cell lysis was performed during 10 min by adding 500 µl ice-cold lysis buffer (50 mM Tris-HCL, pH 7.4, 150 mM NaCl, 1% TritonX-100, protease and phosphatase inhibitor cocktail). The cellular debris was removed by centrifugation at 13000xg for 5 min at 4°C, and the total protein content was measured using BCA Protein Assay Reagent (Pierce, Rockford, IL, USA). Aliquots corresponding to 5 µg of protein were mixed with sodium dodecyl sulfate (SDS) loading buffer, applied to 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed by Western blot. Extracellular signal regulated kinase 1/2 (ERK1/2) and protein kinase B (AKT) activation were assayed by incubating PVDF blots with a mouse antiphospho-ERK1/2 antibody (Sigma-Aldrich) and phospho-AKT antibody (New England Biolabs, UK) respectively. Control blots were also run in parallel and probed with rabbit anti-ERK1/2 antibody (Sigma-Aldrich), and total-AKT antibody that recognized both unphosphorylated and phosphorylated forms. The immunoreactive bands were visualized as described above and then measured by quantitative densitometry.

Fig. 1. Minigene design and topological model of the M₃ receptor. (A) A two-dimensional topology of the M₃ human muscarinic receptor sequence is represented (extracellular space at the top and the intracellular space at the bottom). Filled circles represent the amino acid sequence of peptide 3ILoop employed to construct the minigene. (B) Design of the M₃R-3ILoop minigene vector (884 bp) is also depicted: CBP, Calmodulin Binding Peptide; SBP, Streptavidin Binding Peptide; 3ILoop (630 bp), the Third Intracellular Loop of the M₃ human muscarinic receptor. (C) HEK 293 cells were transiently co-transfected with M₃ or M₅ receptor subtypes and M₃R-3ILoop minigene vector. To confirm the transient transfection of minigene in HEK 293 cells, total RNA was isolated and subjected to RT-PCR. The PCR analysis was achieved using primers specific for a CBP + 3ILoop fragment. Separation of the PCR products on 1.5% agarose gels shows the presence of the M₃R-3ILoop minigene RNA by a single 541-bp band. Lane 1 is a 1-kilobase pair DNA ladder; lane 2 is a PCR product from cells transfected with pcDNA-3xHA-M₃; lane 3 corresponds to cells co-transfected with pcDNA-3xHA-M₃ and M₃R-3ILoop minigene; lane 4 corresponds to cells transfected with pcDNA-3xHA-M₅; and lane 5, to cells co-transfected with pcDNA-3xHA-M₅ and 3ILoop-M₃ minigene. G3DPH gene was used as housekeeping control.



BRET assays

Forty-eight hours after transfection, HEK293T cells transfected with a constant amount (2 μ g) of cDNA of M₃^{Rluc} and increasing amounts of cDNA of β -arrestin^{GFP2}, were rapidly washed twice in PBS (4% glucose), detached, and resuspended in the same buffer. Cell suspension (40 μ g of protein) was distributed in duplicated into 96-well microplates (either clear-bottomed or white opaque plates) for fluorescence and luminescence determinations). The total fluorescence of cell suspensions was quantified and then divided by the background (mock-transfected cells) in a POLARstar Optima plate reader (BMG, Labtechnologies, Offenbug, Germany) equipped with a high-energy xenon flash lamp, using a 10 nm bandwidth excitation filter of 400 nm and an emission filter of 510 nm. *Renilla luciferase*, total luminescence, was determined on samples incubated 10 min with 5- μ M h-coelenterazine as described below. The background values for total luminescence were negligible, and they were subtracted from sample values.

For BRET measurement, 40 μ g of cell suspensions were distributed in duplicate in 96-well white opaque microplates (Corning, NY) and incubated for 10 min at room temperature in

the absence or presence of carbachol. DeepBlueC substrate (Molecular Probes, OR) was added at a final concentration of 5 μ M, and readings were performed immediately after, using a POLARstar Optima plate-reader that allows the sequential integration of the signals detected with two filter settings [485 nm (440-500 nm) and 530 nm (510-560 nm)]. The ligand-induced BRET signal is calculated by subtracting the ratio of emission through the acceptor wavelength window over emission through the donor wavelength window for a vehicle-treated cell sample from the same ratio for a second aliquot of the same cells treated with ligand. With this calculation, the vehicle-treated cell sample represents the background, eliminating the requirement for measuring a donor-only control sample. Then, BRET ratio is defined as [(GFP² emission at 500-530)/(Rluc emission 440-500)] - cf., where cf. corresponds to (emission at 500-530)/(emission at 440-500) for the vehicle-treated cell sample in the same experiment.

Data analysis

All binding data were analyzed using the commercial program GraphPad PRISM 4.0 (GraphPad Prism, San Diego, CA, USA). Basal binding was defined as [³⁵S]-GTP γ S binding

without agonist in the [³⁵S]-GTPγS binding assay. For each agonist concentration, the percentage of binding over basal was calculated to determine the agonist-stimulated [³⁵S]-GTPγS binding. Data were fit to a sigmoidal dose-response curve. For statistical evaluation of the biochemical data, unless otherwise specified, one-way analysis of variance (ANOVA) was used followed by Tukey's Multiple Comparison post-test. *P* values less than 0.05 were considered significant.

Results

Design, construction and expression of 3ILoop-minigene

To determine whether the expression of the M₃-3ILoop peptide could function as an M₃R analogue, we generated a minigene vector that encodes the M₃R-3ILoop and a set of peptides (Calmodulin Binding Peptide/Streptavidin Binding Peptide (CBP/SBP)) as described in Materials and Methods (Fig. 1B). HEK293T cells were transiently co-transfected with the M₃R-3ILoop minigene and the M₃R mAChR. Total RNA was isolated 48 hours post-transfection and analyzed by RT-PCR, using a set of primers that spanned the vector (SBP) and inserted sequence (3ILoop), to confirm the transcription of the M₃R-3ILoop minigene. The presence of a single 541-base pair band corresponding to the RT-PCR product confirmed the transfection of cells with the minigene construct (Fig. 1C). To verify the expression of M₃R-3ILoop peptide in the transfected HEK293T cells, 48 h post-transfection cells were also harvested and subjected to SDS-PAGE and western blot. A band of approximately 24 kDa molecular mass, corresponding to the expected mass of the designed 3ILoop peptide, was identified in cells that have been transfected with the minigene construct.

Effect of M₃R-3ILoop minigene on receptor expression and ligand binding

The K_d values, for [³H]-NMS binding to membranes, gained from cells expressing the M₃R in the presence and in the absence of the M₃R-3ILoop minigene were not significantly different (Table 1). It is also noticeable that the expression of the M₃R-3ILoop minigene did not alter the receptor density (B_{max} value) of the M₃R (Table 1).

HEK293T cells expressing M₅R mAChR were co-transfected with M₃R-3ILoop minigene to determine whether the M₃R-3ILoop protein had any effect on the thermodynamic properties of a related G_{q/11}-coupled receptor, the M₅R. Interestingly, M₅R showed similar

Receptor construct	[³ H]-NMS Binding	
	K _D (pM)	B _{max} (fmol/mg)
3xHA-M ₃	85.3 ± 17.7	1250 ± 106
3xHA-M ₃ + 3ILoop	86.8 ± 27.9	1219 ± 66
3xHA-M ₅	164.9 ± 41.4	934 ± 45
3xHA-M ₅ + 3ILoop	163.7 ± 55.3	908 ± 32

Table 1. Ligand binding properties of M₃ and M₅ mAChR constructs. Radioligand binding studies on HEK293T cell membranes expressing M₃ or M₅ wild type mAChR alone or together with the 3ILoop-minigene were carried out as described under Materials and methods. Curves were better fitted by non-linear regression analysis assuming a single binding site. K_D values were determined by using GraphPad Prism software. Results represent means ± S.E. (n = 5).

specific [³H]-NMS binding properties in the absence or presence of M₃R-3ILoop (Table 1). Overall, these results suggest that M₃R-3ILoop does not affect the conformational state of the orthosteric-binding site of M₃R and M₅R.


M₃R-3ILoop minigene inhibits agonist-mediated stimulation [³⁵S]-GTPγS binding

Since the 3ILoop of M₃R is known to be critical for G-protein coupling and activation [17], the expression of the M₃R-3ILoop minigene might compete for the same pool of G proteins by targeting the receptor-G protein boundary. Therefore, we tested whether the presence of the M₃R-3ILoop minigene, co-transfected in M₃ or M₅ transfected cells, had any effect on G-protein activation which was determined by measuring agonist-induced stimulation of [³⁵S]-GTPγS binding to membranes. The ability of carbachol to stimulate [³⁵S]-GTPγS binding showed a similar maximal response (E_{max}) but different potency (pEC₅₀) when M₃R and M₅R were tested (pEC₅₀ = 4.84 ± 0.04 and pEC₅₀ = 5.77 ± 0.05, respectively; means ± S.D., n = 3, p < 0.05) (Fig. 2).

Interestingly, co-expression of M₃R subtype with M₃R-3ILoop minigene resulted in a significant decrement in E_{max} (~45%) and 2.2 fold increased of pEC₅₀ of the carbachol-mediated [³⁵S]-GTPγS binding, when compared with cells transfected with M₃R alone. We also found that cells expressing the M₅R subtype showed a similar M₃R-3ILoop minigene-mediated change in the agonist-stimulated [³⁵S]-GTPγS binding features (maximal response and potency) (Fig. 2).

To further test the specificity of the function of the 3ILoop of the M₃ receptor to interact with cellular G proteins, we examined the ability of this peptide to modulate agonist-stimulation of specific [³⁵S]-GTPγS

Fig. 2. (A) The 3ILoop-minigene inhibit agonist-stimulated [³⁵S]-GTPγS binding on cells expressing the M₃ and M₅ receptor subtypes. [³⁵S]-GTPγS (0.3 nM) binding to membranes prepared from transiently expressing M₃-HEK293T or M₅-HEK293T cells was measured after incubation at different concentrations of carbachol (CCh) for 1h at 30°C in the presence or absence of M₃R-3ILoop minigene (5μg). Values are expressed as percentage (%) of specific binding to the sample without ligand (control). Data are means ± S.D. from a representative experiment preformed in triplicate. (B) Results of 3ILoop-minigene vector and muscarinic receptor subtypes co-expression on PLC activity in CCh-stimulated HEK293T cells. Cells cotransfected with M₃ or M₅ receptor subtypes and M₃R-3ILoop minigene or empty vector were stimulated with CCh as showed, for 1 hr at 37°C in presence of LiCl as described in “Materials and Methods”. Data are presented as increase of InsPs (DPM) above basal levels in the presence of carbachol. Basal levels viewed with the various receptors were not significantly different. Data represent the average ± S.E.M. values of triplicate determinations of three independent experiments.



binding in cells heterologously expressing G_{i/o}-coupled dopamine D_{2L}-long (D_{2L}) receptor, as well as cells expressing G_{s/olf} adenosine A_{2A} (A_{2A}) receptors. The addition of quinpirole (100nM) in cells expressing D_{2L} receptor or CGS 21680 (100nM) in cells expressing A_{2A} receptor, markedly induced an increase in [³⁵S]-GTPγS binding which was not affected by the expression of the M₃R-3ILoop minigene. These results suggest that M₃R-3ILoop minigene inhibits the G_{q/11} protein-coupled mAChRs-mediated [³⁵S]-GTPγS binding in a specific manner.

Effect of 3ILoop-minigene Expression on PLC Activation

We then analyzed agonist-stimulated Ins-(1,4,5)-P₃ formation in HEK293T cells expressing each receptor subtype and either the minigene or an empty vector to assess whether the presence of the minigene could compete and recruit G protein-mediated activation of receptors. First, we characterized the time- and concentration-dependence of carbachol-stimulated [³H]-myoinositolphosphate ([³H]-myo-InsPs) accumulation in transfected M₃ and M₅-HEK293T cells. [³H]-myo-InsPs accumulation reached a peak between 5-10 min after agonist exposure. Complete desensitization occurred within 30 min of high dose stimulation. Nonappreciable

carbachol-stimulated [³H]-myo-InsPs accumulation was detected in nontransfected cells (Figure not shown).

Fig. 2B shows the concentration-response curves for carbachol-dependent stimulation of [³H]-myo-InsPs in M₃ and M₅-HEK293T cells co-expressing the minigene or the empty vector. Carbachol produced a seven-fold stimulation of inositol phosphate over basal levels, suggesting the presence of endogenous G proteins in HEK293 cells that can effectively activate PLC. In contrast, expression of the minigene vector abolished M₃-agonist [³H]-myo-InsPs accumulation at all agonist concentrations, with a decrease in relative efficacy in about 50%. A similar response was observed in cells expressing M₅ receptors. In this case, carbachol stimulation produced a 6-fold increase in [³H]-myo-InsPs accumulation but co-expression of the minigene vector counteracts agonist stimulation (46% reduction in relative efficacy value compared with M₅ receptor alone).

Besides the change observed in the maximum PLC response, there was a consistent and statistically significant reduction in the potency of carbachol to stimulate Ins-(1,4,5)-P₃ release upon activation of the M₃ or M₅ receptor (pEC₅₀ in the presence of M₃R-3ILoop minigene construct compared with the control, increased 3.1 ± 0.6 fold for the M₃ receptor and 3.4 ± 0.5 fold for the M₅ receptor).

Fig. 3. Expression of the 3ILoop-minigenes inhibit agonist-mediated ERK 1/2 phosphorylation. (A) Time-dependent course of ERK1/2 activation on CCh-stimulated M₃-HEK293T cells transfected or not with M₃R-3ILoop minigene. Cells were incubated with 1 mM of CCh for the showed time points. (B) Densitometry analysis of time course of ERK1/2 activation following CCh exposure is shown. Phosphorylation was quantified by scanning densitometry using the NIH Image program and normalized against total ERK1/2 protein. Means \pm S.E.M are shown; n= 6. *Significantly different compared with M₃-15min (ANOVA: p<0.05); **Significantly different compared with M₃-5min (ANOVA: p<0.01). (C) Western blot analysis for phospho-ERK1/2 (p-ERK) following incubation with 1 mM of carbachol for 5 min. In HEK293T cells transiently expressing M₃ or M₅, co-transfected with the M₃R-3ILoop minigene (5 μ g) (lanes 4 and 6 respectively) or empty vector (lanes 3 and 5). M₃-HEK293T cells, nonstimulated with carbachol (lane 1) and carbachol-stimulated M₃-HEK293T in the presence of MAPK specific inhibitor PD-98059 (lane 2), were analyzed as internal control samples. Equal loading was confirmed with antibodies against total ERK1/2.

To ensure that EC₅₀ and E_{max} changes viewed were not due to changes in the receptor density, we plotted the negative logarithm of EC₅₀ vs. receptor density for experiments with co-expression of the minigene. Although receptor expression was rather variable, EC₅₀ shifts were independent of receptor density (data not shown).

Inhibition of ERK 1/2 and AKT activation is mediated by the expression of minigene construct

Previous experimental evidence supports the idea that at least two distinct mechanisms are involved in activation of ERK1/2 pathway by muscarinic receptors, PCK-dependent and/or state receptor phosphorylation dependent [19, 20]. As mentioned above, expression and ligand-binding capacity of M₃ and M₅ receptor subtypes were unaffected by the presence of minigene vector, whereas coupling to G_{q/11} proteins was altered. Consequently, carbachol failed to stimulate phosphatidylinositol production. We evaluated whether the expression of minigene could further alter ERK1/2 signal transduction after agonist stimulation, and if this vector could be used as a potential inhibitor of this GPCR signaling.

First, a time course for ERK 1/2 activation was performed (Fig. 3A). Stimulation of both M₃ receptors co-transfected with empty vector or with minigene, by 20 μ M carbachol, caused maximal activation of ERK1/2 at 5 min. However, Fig. 3B shows that ERK1/2 activation by carbachol in cells co-transfected with the minigene was significantly lower than ERK1/2 activation in cells transfected with an empty vector (4-fold in less, P<0.01).




Fig. 3C shows the effects of minigene co-transfection on MAPK activity in cells expressing either M₃ or M₅ receptor subtypes. A significant decrease in ERK1/2 phosphorylation was observed in both cases when compared with activation in the absence of minigene vector. Preincubation with the MEK specific inhibitor PD-98059 inhibited carbachol-induced ERK1/2 phosphorylation to the same extent as that obtained in cells co-transfected with the minigene construct. This confirmed that M₃R-3ILoop minigene vector acts as an efficient inhibitory protein of the MAPK signaling pathway after agonist stimulation.

Carbachol binding to the G_{q/11} muscarinic receptors stimulates AKT-mediated cell growth and survival in many cell types [21]. Therefore, the effect of minigene expression on carbachol-induced AKT-activation was also studied.

Activating M₃ or M₅-expressing cells by carbachol incubation reaches a maximum of AKT phosphorylation




Fig. 4. 3ILoop effect on AKT phosphorylation mediated upon muscarinic receptor activation. (A) HEK293T cells co-transfected with each receptor subtype and the M₃R-3ILoop minigene (lanes 4 and 6 respectively) or empty vector (lanes 3 and 5) were exposed to 1 mM CCh for 10 min after 48 h of transfection. Cell lysates were resolved by SDS-PAGE (12%) and Western blots performed with an antibody against phosphorylated AKT. Nonstimulated M₃-HEK293T cells (lane 1) and CCh-stimulated M₃-HEK293T in the presence of a selective PI3K inhibitor, LY294002 (lane 2) were assayed as internal controls. Equal loading was confirmed with rabbit anti-AKT antibody (New England Biolabs, UK). (B) The extent of AKT phosphorylation was quantified by scanning densitometry. Means \pm S.E.M is shown; n = 4. **Significantly different compared with M₃ (ANOVA: p<0.01). ##Significantly different compared with M₅ (ANOVA: p<0.01).

at 10 min after stimulation. No activation occurred in cells pre-incubated with the PI3K antagonist LY294002 as shown in Fig. 4A-B. Western blot analysis revealed that, as previously noted in ERK1/2 signaling, co-transfection of M₃-or M₅-HEK293T with the minigene vector abolished the phosphorylation of AKT after agonist stimulation (Fig. 4A-B).




Fig. 5. Modulation of scaffold proteins association by co-expression of 3ILoop. (A) HEK293T cells co-transfected with M₃ receptor, in the presence or absence of the M₃R-3ILoop minigene, plus each of the following proteins, β -arrestin-GFP, Flag-GRK-2 or Flag-CK1- α , were stimulated with CCh before solubilization. Extracts were immunoprecipitated with anti-HA antibody (or nonimmune IgG control) before Western blotting. At the top sections, the immunoprecipitation was probed with an antibody against the M₃ muscarinic receptor (goat anti-M₃R antibody, 1:1000; Santa Cruz Biotechnology). The middle sections show specific co-immunoprecipitation with β -arrestin-GFP (mouse anti-GFP monoclonal antibody, 1: 10000; Novus Biological). A low-level of specific pulldown of β -arrestin-GFP can be seen when cells are co-expressed with the 3ILoop minigene construct. Similar effects were remarked in the bottom sections when immunoprecipitations were probed with anti-FLAG antibody for both kinases (GRK-2 and CK1- α) under the same conditions (mouse anti-flag M2 monoclonal antibody, 1:5000; Sigma-Aldrich). The right panel (positive control) represents the input levels of immunoreactive M₃ receptor, β -arrestin-GFP, Flag-GRK-2 or Flag-CK1- α in original extracts. Interacting protein co-immunoprecipitated was normalized for immunoprecipitated 3xHA-M₃ receptor. Blots are representative of at least three separate experiments. (B) The extent of scaffold protein immunoprecipitation was quantified by scanning densitometry. Data are the means \pm S.E.M. from three separate experiments. (**) P<0.01 and (***) P<0.001.




Fig. 6. Assessment of receptor stimulated β -arrestin recruitment. Cells cotransfected with M_3^{Rluc} and β -arrestin^{GFP2} in presence or absence of 3ILoop minigene, were incubated for 20 min at various concentration of agonist or vehicle. The luciferase substrate DeepBluC coelenterazine was added immediately prior to BRET measurement. Data shown are means \pm S.E.M of the five independent experiments.

Modulation of receptor functions by sequestration of accessory proteins

Considering the dramatic decrease in ERK1/2 phosphorylation in cells expressing the minigene construct, we decided to analyze whether the minigene expression could modulate receptor function by sequestering receptor scaffold or accessory protein.

At least one of the two mechanisms described for MAPK activation by muscarinic receptor family could involve scaffold proteins, such as β -arrestin and kinases (GRK-2, GRK-3 and CK1- α), which form a direct complex with the receptor.

Co-immunoprecipitation experiments were carried out to discover if the direct complex formation had been altered or blocked by the presence of the cytoplasmatic 3ILoop. Fig. 5A shows co-immunoprecipitation data from HEK293T cells co-transfected with HA-M₃ receptor in the presence or absence of 3ILoop-M₃ minigene and each of the following vectors: β -arrestin-GFP2, Flag-GRK-2 and Flag-CK1- α .

Input levels of each protein and the efficiency of M₃ receptor immunoprecipitation were checked to ensure a balance between samples. In addition, we also analyzed the input level of immunoreactive M₃ receptor, β -arrestin-GFP, Flag-GRK-2 or Flag-CK1- α in original extracts as a positive control of each antibody quality (Fig. 5A, right lane). In all cases, low levels of immunoreactivity were associated with the receptor in basal conditions. However, preincubation of the cells with carbachol caused an increased association of each protein to the M3 receptor, as checked by densitometry of the immunoblots (Fig. 5B). Co-transfection with 3ILoop-M₃ minigene, as well as agonist preincubation, caused a decrease in immunoreactivity for each protein to a level similar to that found

under basal conditions. These low levels of co-immunoprecipitation probably resulted from the competition of the M₃R-3ILoop minigene with the same pool of proteins interacting with the receptor, thus blocking their association to the third intracellular loop. Co-immunoprecipitation results could also account for low signal levels gained in ERK 1/2 phosphorylation assays in the presence of the 3ILoop.

To determine whether sequestration of accessory proteins by the 3ILoop peptide affects their ability to modulate M3 receptor function, we used a BRET assay to determine if the 3ILoop peptide interferes with β -arrestin recruitment. β -arrestin has been shown to be particularly amenable to BRET analysis, and BRET has been used previously to investigate GPCR- β -arrestin and β -arrestin-ubiquitin interactions in parallel [22, 23]. The advantage of BRET compared with a number of other methods is that it is possible to observe interactions in living cells over time, in the presence of agonists and antagonists. We assayed carbachol-induced (1 μ M) interactions between M₃ receptor and β -arrestins-1 for 1 min pre-treatment and 120 min post-treatment (different intervals), observing a maximum BRET ratio between 5-20 min (data not shown). In addition, the ability of carbachol to stimulate BRET signal was tested in presence or absence of the 3ILoop. Co-expression of M₃^{Rluc} and β -arrestin^{GFP2} in presence of 3ILoop minigene led to a substantial reduction in BRET signal versus M₃^{Rluc} and β -arrestin^{GFP2} pair, as seen from the marked reduction of the BRET values (Fig. 6A). These results are consistent with those observed in western blot experiments (Fig. 6B) and phosphorylation level (data not shown) determination; where the presence of 3ILoop produced a dramatic decrease in β -arrestin binding and receptor

phosphorylation upon agonist activation.

Discussion

As part of an effort to define the potential role of the 3ILoop in protein-protein interactions and multiprotein complex organization, we report here the co-expression of a minigene construction that encoded the 3ILoop of the M_3 human muscarinic receptor with the intact receptor.

The rationale of this approach was to explore the ability of this structural determinant to interfere with G protein interaction or to compete for other interacting proteins that took part in a putative multiprotein complex formation. Our efforts were specifically focused on the 3ILoop of the M_3 muscarinic receptor subtype, because this region was reported to be involved in direct G protein binding and activation, and the putative site for interaction of a group of scaffold or accessory proteins (arrestin binding, calmodulin and small G protein interactions) [24, 25]. Previous studies of cellular expression of fragments and in vitro G protein activation assays have reported the ability of the intracellular loops -or peptides derived from these loops- to interact with the same molecular partners as the intact receptor [26-28]. These experiments demonstrated that the 3ILoop domain of the M_3 receptor had a recognizable impact on the role of the intact M_3 receptor subtype. In our experiments events occurring at the plasma membrane were dramatically affected in cells co-expressing the 3ILoop minigene construct. Co-expressing the minigene construct with the wild-type receptor decreased G protein activation, phosphatidylinositol production, and subsequent signaling, without effecting normal ligand binding and receptor membrane expression. Our results showed that co-expression of the 3ILoop of the M_3 receptor with the M_5 subtype are similar to previous studies of the 3ILoop of the μ -opioid receptor, which altered the functionality of the intact μ -opioid receptor as well as other classes of GPCR [29].

While we only focused on the study of the effect of the 3ILoop, we cannot exclude the possible involvement of the first and second cytoplasmic loops or the C-terminal tail. Thus, although the 3ILoop is the largest intracellular loop, and is usually proposed to be one of the main sites for intracellular interaction, this does not exclude specific domains in other loops from playing a role in protein-protein interactions such as the formation of a multiprotein complex formation. In fact, the C-terminal tail is recognised to be an important structural determinant with antiapoptotic properties within the muscarinic receptor

family [30] and the second intracellular loop, with the DRY motif, has also been described to bind the G protein [31].

In our experimental design, we chose to express the intracellular domain with two-epitope tags (CBP-SBP: TAP-system) at the N-terminal domain to purify the recombinant receptor. This will also allow us to develop further studies using mass spectrometry in order to discover the nature of the interacting proteins. The possibility of conformational and accessibility changes in potentially critical regions close to these tags was unlikely because of their small size (fewer than 15 aa). However, to ensure the proper construct was correctly incorporated into the cell, we used a RT-PCR strategy that involved primers spanning vector and insert sequences that would have been absent in the intact receptor construct.

We found that our minigene-system was able to reduce the mAChR-mediated G protein activation as much as 45%. These observations are consistent with those of other groups using a similar experimental approach with other GPCRs, such as δ -opioid, μ -opioid and α_2 -adrenergic receptors [29]. Upon co-expression of the minigene with the M_5 subtype, we also noted low affinity levels with agonist-stimulated [35 S]-GTP γ S, and a decrease in efficacy. Overall, these experiments suggest that the minigene interferes with the specific function of the $G_{q/11}$ protein pool that couples with M_3 as well as with M_5 subtypes. Supporting this observation, we showed changes in the second messenger levels following expression of the minigene in intact cells. Agonist-mediated activation of Ins-(1,4,5)-P₃ accumulation was blocked in the presence of the minigene, in cells expressing either M_3 or M_5 subtypes. Nevertheless, for M_5 subtype, the inhibitory effect of the 3ILoop was less pronounced. We also saw a decrease, not only in the maximal accumulation of phosphatidylinositol, but also in the potency of carbachol concentration-response curves, indicative of a reversible and competitive process. Our results are consistent with those previously reported for angiotensin receptor, where the presence of the second intracellular loop of angiotensin AT1a receptor resulted in a rise in the angiotensin II concentration needed for 50% stimulation for Ins-(1,4,5)-P₃ release [32].

The low sequence homology within these receptors (at the level of 3ILoop) cannot account for the significant effect detected for the minigene impairment of receptor-G protein coupling process, suggesting that structural G-protein interaction sites are similar in both receptors [33]. This idea is consistent with the substantial reduction of Ins-(1,4,5)-P₃ production and G protein activation, which,

however, did not decrease more than 50% with regard to the wild type. This indicates that multiple distinct structural domains could be involved in this interaction, as seen for dopamine and M₁ muscarinic receptors [16]. An alternative explanation is that the relevant domain that interacts with the G protein is exposed in the natural receptor, while the adapted minigene may not present or contain this structure, and therefore does not effectively compete for the binding with its homologous partner.

Several lines of evidence show that muscarinic receptors can activate the MAPK pathway in various ways, dependent on or independent of the classical G-protein activation pathway [20]. One of these mechanisms is PKC-dependent and is essential in ERK activation; it can involve $\beta\gamma$ -subunits and G _{$\alpha_{q/11}$} -subunits. Other mechanisms may depend more on the phosphorylation state, and are mediated by a group of different kinases, like GRK2/3 or CK1 α , recruiting β -arrestin scaffold protein or other adapter proteins, respectively. Our experiments showed that cells co-expressing the minigene construct failed to phosphorylate ERK1/2 upon receptor activation, suggesting that PKC-dependent mechanism, as well as other mechanisms, which depend upon a group of kinases and accessory proteins, have been blocked.

In addition, using immunoprecipitation and bioluminescent assays, we analyzed whether the intact receptor, once activated, loses its ability to recruit and bind CK1 α or β -arrestin in the presence of the minigene. This may help us understand whether the dramatic blockade of ERK1/2 phosphorylation observed involves the inhibitory effects of the minigene construct at the level of the G protein. Our immunoprecipitation and bioluminescent experiments showed a loss of CK1 α and β -arrestin respectively, in the presence of the minigene in comparison with the wild type receptor. Taking this observation into consideration, one possible scenario is that the minigene construct not only disrupts the G subunit association, but also acts as an inhibitory or competitor subunit that potentially disrupts the multiprotein complex formation at the third intracellular loop, thus resulting in a markedly reduced ERK1/2 phosphorylation upon M3 receptor activation. Thus, the specific recruitment of accessory/scaffold proteins by the 3ILoop may be important for their ability to modulate M3 receptor function.

The M3 3ILoop is 256 residues long, containing multiple motifs of basic and acidic residues and some currently recognized functional sequence motifs. This primary sequence pattern is not conserved throughout the G protein-coupled receptor superfamily, and not even within the class A rhodopsin-like receptor subfamily that

represents the closest structurally related class of GPCRs. This may eventually form a conformational structural motif that will be more broadly representative and determine part of the specificity for each receptor in these families. However, no structural data are available to confirm or refute this hypothesis.

Interacting proteins for such motifs appearing in a modular form can be identified by affinity purification approaches, such as yeast two-hybrid screening and immunoprecipitation. Our current work, in which the minigene construct representing the 3ILoop of the M₃ muscarinic receptor specifically influences the intracellular signaling of the intact receptor, probably blocking putative multiprotein complex formation, supports the notion that important motifs could be present in this region. The fact that this loop is long could make it an ideal tool for exploring potential molecular partners that might mediate the observed effect under different cellular conditions. The use of a TAP-system strategy that complements the co-expression experiments of the construct with the intact receptor under different physiological conditions would be a productive approach to study protein-protein interactions, not only for muscarinic receptors but also for other types of GPCR.

In summary, our results suggest that the presence of the M₃R-3ILoop minigene construct not only prevents G-protein coupling to M₃ receptors, but also impairs coupling of other GPCRs that selectively interact with the same G protein population (G _{$q/11$}). We found that the minigene construct can inhibit the M₃ muscarinic acetylcholine signal transduction pathway and its functionality, probably by recruiting M₃R interacting proteins as confirmed by co-immunoprecipitation and bioluminescent experiments. These results highlight the functional relevance of the interplay among GPCRs and selective G-protein pools, a key process for cell regulation. Furthermore, muscarinic receptor-derived peptides could be used as selective inhibitors for protein-protein interaction, this may be useful for developing a novel pharmacological strategies.

Acknowledgements

This study was supported by the Ministerio de Ciencia e Innovación, Gobierno de España (Grants SAF2005-0848-C04-02 and SAF2002-0345-C0302 to P.G.; and SAF2008-01462 and CSD2008-00005 to F.C.); by European Social Foundation and Gobierno de Catalunya (FI2004-BE2006 to D.O.B-E); and from the

Swedish Research Council (04X-715), Torsten and Ragnar Söderberg Foundation to KF. F.C belongs to the "Neuropharmacology and Pain" accredited research group (Generalitat de Catalunya, 2009 SGR 232).

We infinitely appreciate the assistance and comments provided by Margaret Carr during correction of the manuscript.

References

- 1 Caulfield MP, Birdsall NJ: International union of pharmacology. XVII. Classification of muscarinic acetylcholine receptors. *Pharmacol Rev* 1998;50:279-290.
- 2 Ishii M, Kurachi Y: Muscarinic acetylcholine receptors. *Curr Pharm Des* 2006;12:3573-3581.
- 3 Nahorski SR, Tobin AB, Willars GB: Muscarinic m3 receptor coupling and regulation. *Life Sci* 1997;60:1039-1045.
- 4 Yamada M, Inanobe A, Kurachi Y: G protein regulation of potassium ion channels. *Pharmacol Rev* 1998;50:723-760.
- 5 Volpicelli LA, Levey AI: Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. *Prog Brain Res* 2004;145:59-66.
- 6 Schmidt M, Rumenapp U, Keller J, Lohmann B, Jakobs KH: Regulation of phospholipase c and d activities by small molecular weight g proteins and muscarinic receptors. *Life Sci* 1997;60:1093-1100.
- 7 Kozma R, Sarner S, Ahmed S, Lim L: Rho family gtpases and neuronal growth cone remodelling: Relationship between increased complexity induced by cdc42hs, rac1, and acetylcholine and collapse induced by rhoa and lysophosphatidic acid. *Mol Cell Biol* 1997;17:1201-1211.
- 8 Linseman DA, Heidenreich KA, Fisher SK: Stimulation of m3 muscarinic receptors induces phosphorylation of the cdc42 effector activated cdc42hs-associated kinase-1 via a fyn tyrosine kinase signaling pathway. *J Biol Chem* 2001;276:5622-5628.
- 9 Firth TA, Jones SV: Gtp-binding protein gq mediates muscarinic-receptor-induced inhibition of the inwardly rectifying potassium channel irkl (kir 2.1). *Neuropharmacology* 2001;40:358-365.
- 10 Eglén RM: Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. *Auton Autacoid Pharmacol* 2006;26:219-233.
- 11 van Koppen CJ, Kaiser B: Regulation of muscarinic acetylcholine receptor signaling. *Pharmacol Ther* 2003;98:197-220.
- 12 Simon V, Guidry J, Gettys TW, Tobin AB, Lanier SM: The proto-oncogene set interacts with muscarinic receptors and attenuates receptor signaling. *J Biol Chem* 2006;281:40310-40320.
- 13 Borroto-Escuela DO, Ciruela F: Muscarinic receptor-associated proteins: More than just an interaction between proteins. Nova Science Publishers, 2007.
- 14 Adem A, Karlsson E: Muscarinic receptor subtype selective toxins. *Life Sci* 1997;60:1069-1076.
- 15 Nelson CP, Challiss RA: "Phenotypic" Pharmacology: The influence of cellular environment on g protein-coupled receptor antagonist and inverse agonist pharmacology. *Biochem Pharmacol* 2007;73:737-751.
- 16 Hawes BE, Luttrell LM, Exum ST, Lefkowitz RJ: Inhibition of g protein-coupled receptor signaling by expression of cytoplasmic domains of the receptor. *J Biol Chem* 1994;269:15776-15785.
- 17 Liu J, Blin N, Conklin BR, Wess J: Molecular mechanisms involved in muscarinic acetylcholine receptor-mediated g protein activation studied by insertion mutagenesis. *J Biol Chem* 1996;271:6172-6178.
- 18 Zhang Y, Wang D, Sadee W: Calmodulin interaction with peptides from g-protein coupled receptors measured with s-tag labeling. *Biochem Biophys Res Commun* 2005;333:390-395.
- 19 Budd DC, McDonald JE, Tobin AB: Phosphorylation and regulation of a gq/11-coupled receptor by casein kinase Ialpha. *J Biol Chem* 2000;275:19667-19675.
- 20 Budd DC, Willars GB, McDonald JE, Tobin AB: Phosphorylation of the gq/11-coupled m3-muscarinic receptor is involved in receptor activation of the erk-1/2 mitogen-activated protein kinase pathway. *J Biol Chem* 2001;276:4581-4587.
- 21 Cui QL, Fogle E, Almazan G: Muscarinic acetylcholine receptors mediate oligodendrocyte progenitor survival through src-like tyrosine kinases and pi3k/akt pathways. *Neurochem Int* 2006;48:383-393.
- 22 Perroy J, Pontier S, Charest PG, Aubry M, Bouvier M: Real-time monitoring of ubiquitination in living cells by bret. *Nat Methods* 2004;1:203-208.
- 23 Kocan M, Pflieger KD: Detection of gpcr/beta-arrestin interactions in live cells using bioluminescence resonance energy transfer technology. *Methods Mol Biol* 2009;552:305-317.
- 24 Keller J, Schmidt M, Hussein B, Rumenapp U, Jakobs KH: Muscarinic receptor-stimulated cytosol-membrane translocation of rhoa. *FEBS Lett* 1997;403:299-302.
- 25 Novi F, Stanasila L, Giorgi F, Corsini GU, Cotecchia S, Maggio R: Paired activation of two components within muscarinic m3 receptor dimers is required for recruitment of beta-arrestin-1 to the plasma membrane. *J Biol Chem* 2005;280:19768-19776.
- 26 Gilchrist A, Li A, Hamm HE: Design and use of c-terminal minigene vectors for studying role of heterotrimeric g proteins. *Methods Enzymol* 2002;344:58-69.
- 27 Abdulaev NG, Ngo T, Chen R, Lu Z, Ridge KD: Functionally discrete mimics of light-activated rhodopsin identified through expression of soluble cytoplasmic domains. *J Biol Chem* 2000;275:39354-39363.
- 28 Hayashida W, Horiuchi M, Dzau VJ: Intracellular third loop domain of angiotensin II type-2 receptor. Role in mediating signal transduction and cellular function. *J Biol Chem* 1996;271:21985-21992.
- 29 Morou E, Georgoussi Z: Expression of the third intracellular loop of the delta-opioid receptor inhibits signaling by opioid receptors and other g protein-coupled receptors. *J Pharmacol Exp Ther* 2005;315:1368-1379.
- 30 Tobin AB, Budd DC: The anti-apoptotic response of the gq/11-coupled muscarinic receptor family. *Biochem Soc Trans* 2003;31:1182-1185.
- 31 Blin N, Yun J, Wess J: Mapping of single amino acid residues required for selective activation of gq/11 by the m3 muscarinic acetylcholine receptor. *J Biol Chem* 1995;270:17741-17748.
- 32 Thompson JB, Wade SM, Harrison JK, Salafranca MN, Neubig RR: Cotransfection of second and third intracellular loop fragments inhibit angiotensin at1a receptor activation of phospholipase c in hek-293 cells. *J Pharmacol Exp Ther* 1998;285:216-222.
- 33 Burstein ES, Spalding TA, Brann MR: Structure/function relationships of a g-protein coupling pocket formed by the third intracellular loop of the m5 muscarinic receptor. *Biochemistry* 1998;37:4052-4058.